LuPARP

Metastatic Castration Resistant Prostate Cancer (mCRPC) research Data from the multicentre trial “PROfound”, presented at the ESMO Congress 2019, show that “Olaparib” (poly-ADP ribose polymerase (PARP) inhibitor) delayed cancer progression by about four months and prolonged overall survival by over three months, compared to the latest forms of hormonal treatment (enzalutamide or abiraterone acetate) in patients …

Israeli Nuclear Medicine Conference INM

This month (7-9.3.19) Isotopia took part in the Nuclear Medicine Conference organized by Prof. Bar Saver.  The annual congress of the Israeli Society of Nuclear Medicine is the main and largest national nuclear medicine meeting, bringing together all disciplines involved in nuclear medicine in Israel. At this conference, a lecture given on the use of …

Management

Dr. Eli Shalom CEO & Co- Founder  Linkedin An experienced radiopharmacist. Prior to founding Isotopia he was involved for eight years in the research and development and production of SPECT and PET isotopes in the National Nuclear Research Center at Nahal Soreq. With a Ph.D degree from the Hebrew University (Jerusalem) in the Synthesis of …